Press Releases July 29, 2026 04:05 PM

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELA Bio to Present at Canaccord Genuity 46th Annual Growth Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
TELA

TELA Bio, a NASDAQ-listed medical technology company specializing in soft-tissue reconstruction solutions, announced its participation and management presentation at the upcoming Canaccord Genuity 46th Annual Growth Conference scheduled for August 12, 2026.

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TELA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • TELA Bio is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction.
  • The company will present at a notable industry growth conference, providing an opportunity to communicate its strategy and progress to investors.
  • TELA Bio's technology emphasizes preservation and restoration of the patient's own anatomy, targeting improved clinical outcomes with economically effective solutions.

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference.

TELA’s management is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference at 8:30 am ET on August 12th, 2026. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Investor Contact
Louisa Smith
[email protected]


Risks

  • The announcement is primarily a conference participation notice and provides no new financial or product development information, which may limit immediate investor impact.
  • Market reception could be influenced by the content and tone of the upcoming presentation, which is yet to be disclosed.
  • Competitive pressures in the medical technology sector for soft-tissue reconstruction may affect the company's growth prospects.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026